Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

FDA grants Bristol Myers Squibb accelerated approval for Zenbexus (iberdomide), a CELMoD agent, for multiple myeloma
Small molecule, cancer, CELMoD degrader, multiple myeloma, relapsed or refractory multiple myeloma, combination therapy - Read more

Enigma Biomedical USA wins FDA approval for TAUKLARIFY (florquinitau F 18) targeting tau pathology in Alzheimer's disease evaluation
Diagnostic imaging, neurological, PET imaging, Alzheimer's disease, tau protein, radiodiagnostic agent - Read more

Science 2 Sales is the outbound engine for companies selling into biotech & pharma. We handle the market intelligence, prospect scoring, email sequences, LinkedIn outreach, and cold calling - so your sales team inherits a full calendar of qualified meetings.

Built by biopharma BD & sales reps, exclusively for biopharma commercial teams. It’s the platform and service we wish we had years ago.

Learn more and book a free strategy call on our website.

Vogenx raises $81.3M IPO, clinical-stage biopharma targeting metabolic serious diseases
Clinical-stage, metabolic disease, small molecule, biopharmaceutical - Read more

Aptevo Therapeutics raises $4.5M via warrant exercise and PIPE for working capital
Clinical-stage, immuno-oncology, multispecific antibody, bispecific - Read more

MagicRNA closes hundreds of millions yuan Series B, advancing in vivo CAR-T immunotherapy platform
In vivo CAR-T, mRNA delivery, autoimmune, cell therapy, LNP platform, clinical-stage - Read more

Zentalis Pharmaceuticals plans $80.5M public offering to fund oncology clinical trials and pre-commercial activities
Oncology, small molecule, clinical-stage, biomarker discovery, ovarian cancer - Read more

BridgeBio Pharma plans secondary offering of 5M shares by existing shareholder KKR
Genetic conditions, small molecule, rare disease, commercial-stage - Read more

Skye Bioscience to acquire Redx Pharma in deal backed by $125M in combined financings
Small molecule, fibrotic disease, major transaction, financial - Read more

Capricor Therapeutics soars after FDA greenlights amendment to DMD cell therapy approval application
Cell therapy, rare disease, regulatory, financial - Read more

Neurocrine Biosciences defends Vykat XR safety amid advocacy groups' concerns over serious adverse events
Small molecule, rare disease, safety, regulatory - Read more

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

Karyopharm Therapeutics faces potential debt default next month as cash reserves near depletion
Small molecule, oncology, financial, strategic - Read more

Cytokinetics files patent complaint against Bristol Myers Squibb over MYQORZO heart disease therapy infringement claims
Small molecule, cardiovascular, competitive, regulatory - Read more

Bristol Myers Squibb faces revived Celgene shareholder lawsuit over $6B CVR Breyanzi agreement
CAR-T, oncology, contingent value rights, financial - Read more

AstraZeneca's Baxfendy fails ICER cost-effectiveness threshold at $10,800 annual list price
Small molecule, cardiovascular, regulatory, competitive - Read more

Amgen's Tavneos loses EU approval after regulators cite "serious breaches" in pivotal trial data
Small molecule, rare disease, regulatory, financial, operational - Read more

MapLight Therapeutics pauses preclinical programs, raises $150M to advance ML-007C-MA toward phase 3 schizophrenia trial
Small molecule, neurological, strategic, cost reduction - Read more

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here